vs
豪洛捷（HOLX）与Sabre Corp（SABR）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是Sabre Corp的1.8倍（$1.0B vs $592.0M），豪洛捷净利率更高（17.1% vs -17.5%，领先34.6%），Sabre Corp同比增速更快（2.9% vs 2.5%），过去两年豪洛捷的营收复合增速更高（1.5% vs -13.0%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Sabre Corporation是总部位于美国得克萨斯州南湖的旅游科技公司，也是全球最大的航空预订全球分销系统（GDS）服务商。其核心产品Sabre全球分销系统作为中立中介，连接航司、酒店等旅游供应商与旅行社等旅游销售方，提供实时库存与价格信息，是企业差旅管理领域的重要服务商。
HOLX vs SABR — 直观对比
营收规模更大
HOLX
是对方的1.8倍
$592.0M
营收增速更快
SABR
高出0.3%
2.5%
净利率更高
HOLX
高出34.6%
-17.5%
两年增速更快
HOLX
近两年复合增速
-13.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $592.0M |
| 净利润 | $179.1M | $-103.5M |
| 毛利率 | 56.0% | 55.4% |
| 营业利润率 | 22.6% | 1.6% |
| 净利率 | 17.1% | -17.5% |
| 营收同比 | 2.5% | 2.9% |
| 净利润同比 | -10.9% | -38.6% |
| 每股收益（稀释后） | $0.79 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXSABR
| Q4 25 | $1.0B | $592.0M | ||
| Q3 25 | $1.0B | $715.2M | ||
| Q2 25 | $1.0B | $687.1M | ||
| Q1 25 | $1.0B | $776.6M | ||
| Q4 24 | $1.0B | $575.6M | ||
| Q3 24 | $988.0M | $691.3M | ||
| Q2 24 | $1.0B | $695.0M | ||
| Q1 24 | $1.0B | $782.9M |
净利润HOLXSABR
| Q4 25 | $179.1M | $-103.5M | ||
| Q3 25 | $187.2M | $848.5M | ||
| Q2 25 | $194.9M | $-256.5M | ||
| Q1 25 | $-17.4M | $35.5M | ||
| Q4 24 | $201.0M | $-74.7M | ||
| Q3 24 | $178.6M | $-62.8M | ||
| Q2 24 | $194.5M | $-69.8M | ||
| Q1 24 | $169.9M | $-71.5M |
毛利率HOLXSABR
| Q4 25 | 56.0% | 55.4% | ||
| Q3 25 | 55.6% | 56.2% | ||
| Q2 25 | 56.3% | 56.9% | ||
| Q1 25 | 37.5% | 57.0% | ||
| Q4 24 | 56.8% | 58.8% | ||
| Q3 24 | 56.4% | 57.4% | ||
| Q2 24 | 55.4% | 57.8% | ||
| Q1 24 | 53.3% | 59.0% |
营业利润率HOLXSABR
| Q4 25 | 22.6% | 1.6% | ||
| Q3 25 | 22.6% | 13.1% | ||
| Q2 25 | 24.9% | 13.0% | ||
| Q1 25 | -0.7% | 13.3% | ||
| Q4 24 | 22.5% | 6.5% | ||
| Q3 24 | 23.3% | 8.4% | ||
| Q2 24 | 24.1% | 7.0% | ||
| Q1 24 | 20.7% | 12.5% |
净利率HOLXSABR
| Q4 25 | 17.1% | -17.5% | ||
| Q3 25 | 17.8% | 118.6% | ||
| Q2 25 | 19.0% | -37.3% | ||
| Q1 25 | -1.7% | 4.6% | ||
| Q4 24 | 19.7% | -13.0% | ||
| Q3 24 | 18.1% | -9.1% | ||
| Q2 24 | 19.2% | -10.0% | ||
| Q1 24 | 16.7% | -9.1% |
每股收益（稀释后）HOLXSABR
| Q4 25 | $0.79 | $-0.08 | ||
| Q3 25 | $0.84 | $1.98 | ||
| Q2 25 | $0.86 | $-0.65 | ||
| Q1 25 | $-0.08 | $0.09 | ||
| Q4 24 | $0.87 | $-0.20 | ||
| Q3 24 | $0.75 | $-0.16 | ||
| Q2 24 | $0.82 | $-0.18 | ||
| Q1 24 | $0.72 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $791.6M |
| 总债务越低越好 | $2.5B | $4.3B |
| 股东权益账面价值 | $5.2B | $-1.0B |
| 总资产 | $9.2B | $4.5B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXSABR
| Q4 25 | $2.4B | $791.6M | ||
| Q3 25 | $2.2B | $661.7M | ||
| Q2 25 | $1.9B | $426.1M | ||
| Q1 25 | $1.6B | $651.1M | ||
| Q4 24 | $2.0B | $724.5M | ||
| Q3 24 | $2.3B | $668.8M | ||
| Q2 24 | $2.4B | $612.6M | ||
| Q1 24 | $2.2B | $629.1M |
总债务HOLXSABR
| Q4 25 | $2.5B | $4.3B | ||
| Q3 25 | $2.5B | $4.2B | ||
| Q2 25 | $2.5B | $5.1B | ||
| Q1 25 | $2.5B | $5.0B | ||
| Q4 24 | $2.5B | $5.0B | ||
| Q3 24 | $2.5B | $4.9B | ||
| Q2 24 | $2.5B | $4.9B | ||
| Q1 24 | $2.6B | $5.1B |
股东权益HOLXSABR
| Q4 25 | $5.2B | $-1.0B | ||
| Q3 25 | $5.0B | $-950.8M | ||
| Q2 25 | $4.8B | $-1.8B | ||
| Q1 25 | $4.6B | $-1.6B | ||
| Q4 24 | $4.8B | $-1.6B | ||
| Q3 24 | $5.1B | $-1.5B | ||
| Q2 24 | $5.0B | $-1.5B | ||
| Q1 24 | $4.8B | $-1.4B |
总资产HOLXSABR
| Q4 25 | $9.2B | $4.5B | ||
| Q3 25 | $9.0B | $4.4B | ||
| Q2 25 | $8.8B | $4.4B | ||
| Q1 25 | $8.5B | $4.7B | ||
| Q4 24 | $8.7B | $4.6B | ||
| Q3 24 | $9.2B | $4.7B | ||
| Q2 24 | $8.9B | $4.7B | ||
| Q1 24 | $8.7B | $4.7B |
负债/权益比HOLXSABR
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.4% | 4.0% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流HOLXSABR
| Q4 25 | $229.9M | — | ||
| Q3 25 | $355.1M | $33.7M | ||
| Q2 25 | $343.3M | — | ||
| Q1 25 | $169.4M | $-80.6M | ||
| Q4 24 | $189.3M | $75.7M | ||
| Q3 24 | $367.0M | $24.4M | ||
| Q2 24 | $405.8M | $38.2M | ||
| Q1 24 | $292.4M | $-68.1M |
自由现金流HOLXSABR
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | $13.4M | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | $-98.5M | ||
| Q4 24 | $172.5M | $61.0M | ||
| Q3 24 | $350.6M | $5.1M | ||
| Q2 24 | $385.3M | $20.4M | ||
| Q1 24 | $279.6M | $-95.8M |
自由现金流率HOLXSABR
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | 1.9% | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | -12.7% | ||
| Q4 24 | 16.9% | 10.6% | ||
| Q3 24 | 35.5% | 0.7% | ||
| Q2 24 | 38.1% | 2.9% | ||
| Q1 24 | 27.5% | -12.2% |
资本支出强度HOLXSABR
| Q4 25 | 1.4% | 4.0% | ||
| Q3 25 | 1.3% | 2.8% | ||
| Q2 25 | 1.3% | 3.1% | ||
| Q1 25 | 1.5% | 2.3% | ||
| Q4 24 | 1.6% | 2.6% | ||
| Q3 24 | 1.7% | 2.8% | ||
| Q2 24 | 2.0% | 2.6% | ||
| Q1 24 | 1.3% | 3.5% |
现金转化率HOLXSABR
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | 0.04× | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | -2.27× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SABR
| Distribution | $526.8M | 89% |
| Other | $65.2M | 11% |
